Loading...
•
Sep 30
Eli Lilly Q3 2025 Earnings Report
Eli Lilly reported strong third-quarter results, with substantial revenue and earnings growth driven by demand for Mounjaro and Zepbound.
Key Takeaways
Eli Lilly delivered a robust Q3 2025 performance with revenue rising 54% year-over-year to $17.6B, propelled by high volume growth in key products like Mounjaro and Zepbound. EPS and net income saw substantial increases, and the company raised its full-year guidance on the back of continued pipeline and regulatory momentum.
Revenue grew 54% YoY to $17.6B, primarily due to strong volume from Mounjaro and Zepbound.
Reported EPS reached $6.21; non-GAAP EPS was $7.02.
Net income increased to $5.58B, with gross margin reaching 82.9%.
Lilly advanced orforglipron through multiple Phase 3 trials and secured FDA approval for Inluriyo.
Eli Lilly
Eli Lilly
Eli Lilly Revenue by Segment
Eli Lilly Revenue by Geographic Location
Revenue by Segment
Mounjaro Revenue
CapyFin.comZepbound Revenue
CapyFin.comVerzenio Revenue
CapyFin.comRevenue by Geographic Location
U.S. Market Revenue
CapyFin.comInternational Markets Revenue
CapyFin.com Forward Guidance
Eli Lilly raised its full-year 2025 guidance, reflecting continued strong performance, product demand, and regulatory progress.
Positive Outlook
- 2025 revenue guidance raised to $63.0B–$63.5B
- Reported EPS guidance increased to $21.80–$22.50
- Non-GAAP EPS guidance raised to $23.00–$23.70
- Improved performance margin outlook (reported and non-GAAP)
- Continued pipeline and regulatory advancements including orforglipron and Inluriyo
Challenges Ahead
- Lower realized prices remain a headwind
- U.S. price declines impacted by prior-period rebate adjustments
- Higher marketing and selling expenses (+31%) due to promotional efforts
- Increased R&D costs (+27%) from late-stage investments
- Ongoing litigation and restructuring charges impacted Q3 results
Revenue & Expenses
Visualization of income flow from segment revenue to net income